Novartis (NVS) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Novartis Revenue Highlights


Latest Revenue (Y)

$46.66B

Latest Revenue (Q)

$11.83B

Main Segment (Y)

Top 20 products

Main Geography (Y)

Americas

Novartis Revenue by Period


Novartis Revenue by Year

DateRevenueChange
2023-12-31$46.66B-9.97%
2022-12-31$51.83B-1.98%
2021-12-31$52.88B5.97%
2020-12-31$49.90B2.51%
2019-12-31$48.68B-8.44%
2018-12-31$53.17B6.05%
2017-12-31$50.13B1.41%
2016-12-31$49.44B-1.89%
2015-12-31$50.39B-6.05%
2014-12-31$53.63B-8.83%
2013-12-31$58.83B2.21%
2012-12-31$57.56B-3.06%
2011-12-31$59.38B15.15%
2010-12-31$51.56B14.32%
2009-12-31$45.10B5.92%
2008-12-31$42.58B9.34%
2007-12-31$38.95B5.98%
2006-12-31$36.75B12.98%
2005-12-31$32.53B15.15%
2004-12-31$28.25B13.61%
2003-12-31$24.86B7.40%
2002-12-31$23.15B19.74%
2001-12-31$19.34B-11.44%
2000-12-31$21.83B6.93%
1999-12-31$20.42B-11.38%
1998-12-31$23.04B-

Novartis generated $46.66B in revenue during NA 2023, up -9.97% compared to the previous quarter, and up 87.76% compared to the same period a year ago.

Novartis Revenue by Quarter

DateRevenueChange
2024-03-31$11.83B0.45%
2023-12-31$11.78B-2.61%
2023-09-30$12.09B-13.23%
2023-06-30$13.94B5.51%
2023-03-31$13.21B0.92%
2022-12-31$13.09B1.91%
2022-09-30$12.84B-1.86%
2022-06-30$13.09B2.11%
2022-03-31$12.81B-5.24%
2021-12-31$13.52B1.16%
2021-09-30$13.37B0.55%
2021-06-30$13.29B4.73%
2021-03-31$12.69B-2.58%
2020-12-31$13.03B3.92%
2020-09-30$12.54B7.88%
2020-06-30$11.62B-8.55%
2020-03-31$12.71B-0.06%
2019-12-31$12.72B1.87%
2019-09-30$12.48B3.81%
2019-06-30$12.02B4.97%
2019-03-31$11.46B-16.17%
2018-12-31$13.66B20.01%
2018-09-30$11.39B-15.36%
2018-06-30$13.45B4.05%
2018-03-31$12.93B-1.79%
2017-12-31$13.16B3.72%
2017-09-30$12.69B1.58%
2017-06-30$12.49B6.02%
2017-03-31$11.79B-6.51%
2016-12-31$12.61B2.15%
2016-09-30$12.34B-2.67%
2016-06-30$12.68B7.36%
2016-03-31$11.81B-7.76%
2015-12-31$12.80B2.56%
2015-09-30$12.48B-3.19%
2015-06-30$12.90B5.69%
2015-03-31$12.20B-8.63%
2014-12-31$13.35B0.41%
2014-09-30$13.30B-4.65%
2014-06-30$13.95B-2.04%
2014-03-31$14.24B-7.32%
2013-12-31$15.36B5.53%
2013-09-30$14.56B-0.99%
2013-06-30$14.70B3.51%
2013-03-31$14.21B-5.72%
2012-12-31$15.07B7.33%
2012-09-30$14.04B-3.45%
2012-06-30$14.54B4.51%
2012-03-31$13.91B-7.22%
2011-12-31$15.00B-0.25%
2011-09-30$15.03B-0.59%
2011-06-30$15.12B6.34%
2011-03-31$14.22B-1.67%
2010-12-31$14.46B12.82%
2010-09-30$12.82B7.54%
2010-06-30$11.92B-3.52%
2010-03-31$12.36B-6.00%
2009-12-31$13.14B16.43%
2009-09-30$11.29B5.10%
2009-06-30$10.74B8.22%
2009-03-31$9.93B-4.08%
2008-12-31$10.35B-6.18%
2008-09-30$11.03B2.83%
2008-06-30$10.73B4.99%
2008-03-31$10.22B0.44%
2007-12-31$10.17B-

Novartis generated $11.83B in revenue during Q1 2024, up 0.45% compared to the previous quarter, and up 90.39% compared to the same period a year ago.

Novartis Revenue Breakdown


Novartis Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Total anti-infectives net sales$1.20B$1.10B---
Top 20 products$32.14B$32.66B$29.92B$28.65B$26.95B
Anti Infectives sold under Sandoz name$777.00M$707.00M$694.00M$784.00M-
Rest of portfolio$9.16B$9.33B$9.10B$9.07B$7.95B
COPD---$427.00M-

Novartis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Top 20 products (74.27%), Rest of portfolio (21.17%), Total anti-infectives net sales (2.77%), and Anti Infectives sold under Sandoz name (1.80%).

Quarterly Revenue by Product

Product/ServiceJun 23Jun 22Jun 21Jun 20Jun 19
Rest of portfolio$2.45B$2.20B$2.33B$2.08B$2.12B
Top 20 products$8.79B$8.26B$8.23B$7.10B$7.21B
Anti Infectives sold under Sandoz name-$183.00M$161.00M$134.00M-
Total anti-infectives net sales-$276.00M$257.00M--

Novartis's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Top 20 products (78.18%), and Rest of portfolio (21.82%).

Novartis Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
Other countries$20.05B$20.81B$19.04B$21.10B$22.17B
Country of domicile$970.00M$873.00M$800.00M$848.00M$852.00M
CHINA$3.13B$3.05B$2.57B--
JAPAN$2.21B$2.68B$2.80B$2.66B$3.17B
GERMANY$4.28B$4.87B$4.52B$4.12B$4.18B
FRANCE$2.26B$2.52B$2.44B$2.44B$2.71B
Americas$21.54B$20.46B$19.73B--
Europe---$5.12B-
US---$2.49B-
UNITED STATES---$16.28B$17.56B
Asia/Africa/Australasia---$1.34B-
Canada and Latin America---$784.00M-

Novartis's latest annual revenue breakdown by geography, as of Dec 22: Americas (39.57%), Other countries (36.85%), GERMANY (7.86%), CHINA (5.75%), FRANCE (4.15%), JAPAN (4.05%), and Country of domicile (1.78%).

Quarterly Revenue by Country

CountryJun 19
Asia/Africa/Australasia$333.00M

Novartis's latest quarterly revenue breakdown by geography, as of Jun 19: Asia/Africa/Australasia (100.00%).

Novartis Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson$85.15B$22.47B
MRKMerck$60.12B$16.11B
PFEPfizer$58.50B$17.70B
ABBVAbbVie$54.32B$14.46B
NVSNovartis$46.66B$11.83B
AZNAstraZeneca$45.81B$12.68B
BMYBristol-Myers Squibb Company$45.01B$11.89B
SNYSanofi$43.07B$11.12B
LLYEli Lilly and Company$34.12B$11.44B
GSKGSK$30.33B$7.36B
GILDGilead Sciences$27.12B$6.95B

NVS Revenue FAQ


Novartis's yearly revenue for 2023 was $46.66B, representing a decrease of -9.97% compared to 2022. The company's yearly revenue for 2022 was $51.83B, representing a decrease of -1.98% compared to 2021. NVS's yearly revenue for 2021 was $52.88B, representing an increase of 5.97% compared to 2020.

Novartis's quarterly revenue for Q1 2024 was $11.83B, a 0.45% increase from the previous quarter (Q4 2023), and a -10.44% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $11.78B, a -2.61% decrease from the previous quarter (Q3 2023), and a -10.02% decrease year-over-year (Q4 2022). NVS's quarterly revenue for Q3 2023 was $12.09B, a -13.23% decrease from the previous quarter (Q2 2023), and a -5.84% decrease year-over-year (Q3 2022).

Novartis's revenue growth rate for the last 3 years (2021-2023) was -11.76%, and for the last 5 years (2019-2023) was -4.14%.

Novartis's revenue streams in c 22 are Total anti-infectives net sales, Top 20 products, Anti Infectives sold under Sandoz name, and Rest of portfolio. Total anti-infectives net sales generated $1.2B in revenue, accounting 2.77% of the company's total revenue, up 9.09% year-over-year. Top 20 products generated $32.14B in revenue, accounting 74.27% of the company's total revenue, down -1.61% year-over-year. Anti Infectives sold under Sandoz name generated $777M in revenue, accounting 1.80% of the company's total revenue, up 9.90% year-over-year. Rest of portfolio generated $9.16B in revenue, accounting 21.17% of the company's total revenue, down -1.84% year-over-year.

For the fiscal year ending Dec 22, the largest source of revenue of Novartis was Top 20 products. This segment made a revenue of $32.14B, representing 74.27% of the company's total revenue.